ABSTRAK
Tablet lepas lambat merupakan tablet yang di desain untuk melepaskan obatsecara perlahan – lahan di dalam saluran cerna, dengan menggunakan matrikssebagai salah satu komponen utama. Penelitian ini bertujuan untuk memperoleheksipien koproses xanthan gum – amilosa tersambungsilang (Ko-CLA6-XG danKo-CLA12-XG); (CL6-Ko-A-XG dan CL12-Ko-A-XG) sebagai matriks tabletlepas lambat natrium diklofenak. Eksipien Ko-CLA6-XG dan Ko-CLA12-XGmerupakan hasil koproses xanthan gum dengan CLA6 dan xanthan gum denganCLA12. Eksipien CL6-Ko-A-XG dan CL12-Ko-A-XG dihasilkan dengan carasambungsilang dari hasil koproses xanthan gum dan amilosa menggunakannatrium trimetafosfat dengan perbandingan masing – masing eksipien yaitu 1:1,1:2 dan 2:1. Ko-CLA6-XG, Ko-CLA12-XG, CL6-Ko-A-XG dan CL12-Ko-A-XGyang dihasilkan dikarakterisasi sifat fisik, kimia dan fungsional. Ko-CLA6-XGdan Ko-CLA12-XG mempunyai derajat substitusi 0,070 dan 0,110. Eksipien CL6-Ko-A-XG 1:1, 1:2 dan 2:1 berturut – turut 0,077; 0,081 dan 0,083 serta CL12-Ko-A-XG 1:1, 1:2 dan 2:1 berturut – turut 0,113; 0,119 dan 0,122. Eksipien tersebutmempunyai kemampuan mengembang yang baik, viskositas yang cukup besar dankekuatan gel yang baik. Tablet dengan matriks Ko-CLA6-XG, Ko-CLA12-XG,CL6-Ko-A-XG dan CL12-Ko-A-XG diformulasikan dengan metode cetaklangsung dan seluruhnya memenuhi persyaratan evaluasi tablet. Profil pelepasannatrium diklofenak dari tablet yang mengandung matriks Ko-CLA6-XG (F1 –F3), Ko-CLA12-XG (F4 – F6), CL6-Ko-A-XG (F7 – F9) dan CL12-Ko-A-XG(F10 – F12) dalam medium dapar fosfat selama 8 jam, menunjukkan profilpelepasan obat diperlambat dengan kinetika pelepasan orde nol (F1 – F6, F9, F11)dan Korsmeyer-Peppas (F7, F8, F10, F12). Oleh karena itu, F1 – F6 dapatdigunakan untuk sediaan lepas lambat selama 16 jam sedangkan F7 – F12 dapatdigunakan untuk sediaan lepas lambat selama 32 jam.

---

ABSTRACT
Sustained release tablet was solid dosage form which was designed to releasedrugs slowly in gastrointestinal tract. This present research was intended toproduce coprocessed excipient of xanthan gum-crosslinked amylose (Co-CLA6-XG and Co-CLA12-XG); (CL6-Co-A-XG and CL12-Co-A-XG) as matrix forsustained release tablet of sodium diclofenac. Co-CLA6-XG and Co-CLA12-XGwere produced by coprocessing xanthan gum with CLA6 and xanthan gum withCLA12. CL6-Co-A-XG and CL12-Co-A-XG were produced from thecoprocessed xanthan gum and amylose then were crosslinked with sodiumtrimethaphosphate. All excipient had a ratio 1:1, 1:2 and 2:1. The obtained Co-CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG werecharacterized physically, chemically and functionally. The degree of substitution(DS) of Co-CLA6-XG and Co-CLA12-XG were 0,070 and 0,110. Then the DS ofCL6-Co-A-XG 1:1, 1:2 and 2:1 were respectively 0,077; 0,081 and 0,083. The DSof CL12-Co-A-XG 1:1, 1:2 and 2:1 were respectively 0,113; 0,119 and 0,122. Allexcipients had good swelling index, high viscosity and good gel strenght. Tabletswith Co-CLA6-XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG matrixwere formulated by direct compression method and passed tablet evaluation tests.The release profile of sodium diclofenac which contained matrix from Co-CLA6-XG (F1 – F3), Co-CLA12-XG (F4 – F6), CL6-Co-A-XG (F7 – F9) and CL12-Co-A-XG (F10 – F12) in phospate buffer medium for 8 hours, showed that thesustained release profile followed zero order kinetics (F1 – F6, F9, F11) andKorsmeyer-Peppas (F7, F8, F10, F12). Thus, F1 – F6 tablet formulations could beapplied as sustained release tablet formulas and could retard drug release up to 16hours. Then F7 – F12 could be applied as sustained release tablet formula andcould retard drug release up to 32 hours.